Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Rader

Showing results (81-90 of 821) with videos related to

Pageof 83
Sort By:
Circulation|February 25, 2020
Polygenic Risk Scores and Coronary Artery Disease: Ready for Prime Time?Michael G Levin, Daniel J Rader
Nature Medicine|September 11, 2012
The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?Daniel J Rader, Alan R Tall
Annual Review of Medicine|January 16, 2014
Future of cholesteryl ester transfer protein inhibitorsDaniel J Rader, Emil M deGoma
Nature|September 24, 2024
Yo-yo dieting accelerates cardiovascular disease by reprogramming the immune systemDaniel J Rader, Kate Townsend Creasy
Circulation Research|October 12, 2017
Trials and Tribulations of CETP InhibitorsAlan R Tall, Daniel J Rader
Circulation|October 1, 2003
The metabolic syndrome: more than the sum of its parts?Muredach P Reilly, Daniel J Rader
Nature Reviews. Cardiology|January 19, 2011
Novel HDL-directed pharmacotherapeutic strategiesEmil M Degoma, Daniel J Rader
Nature Cell Biology|March 1, 2012
Secreted miRNAs suppress atherogenesisDaniel J Rader, Michael S Parmacek
Current Drug Targets|January 29, 2008
Lipases as modulators of atherosclerosis in murine modelsRobert J Brown, Daniel J Rader
Current Opinion in Cardiology|June 26, 2004
The role of endothelial lipase in high-density lipoprotein metabolismKaren O Badellino, Daniel J Rader
Pageof 83

Showing results (81-90 of 821) with videos related to

Sort By:
Pageof 83
Circulation|February 25, 2020
Polygenic Risk Scores and Coronary Artery Disease: Ready for Prime Time?Michael G Levin, Daniel J Rader
Nature Medicine|September 11, 2012
The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?Daniel J Rader, Alan R Tall
Annual Review of Medicine|January 16, 2014
Future of cholesteryl ester transfer protein inhibitorsDaniel J Rader, Emil M deGoma
Nature|September 24, 2024
Yo-yo dieting accelerates cardiovascular disease by reprogramming the immune systemDaniel J Rader, Kate Townsend Creasy
Circulation Research|October 12, 2017
Trials and Tribulations of CETP InhibitorsAlan R Tall, Daniel J Rader
Circulation|October 1, 2003
The metabolic syndrome: more than the sum of its parts?Muredach P Reilly, Daniel J Rader
Nature Reviews. Cardiology|January 19, 2011
Novel HDL-directed pharmacotherapeutic strategiesEmil M Degoma, Daniel J Rader
Nature Cell Biology|March 1, 2012
Secreted miRNAs suppress atherogenesisDaniel J Rader, Michael S Parmacek
Current Drug Targets|January 29, 2008
Lipases as modulators of atherosclerosis in murine modelsRobert J Brown, Daniel J Rader
Current Opinion in Cardiology|June 26, 2004
The role of endothelial lipase in high-density lipoprotein metabolismKaren O Badellino, Daniel J Rader
Pageof 83